Billing Beat

MolDx Finalizes Expanded Coverage for Liquid Biopsies

February 10, 2020

The policy stipulates that WPSIC will only cover the Guardant360 assay if the patient has a recurrent, relapsed, refractory, metastatic, or advanced solid tumor that didn’t originate from the central nervous system. The Medicare contractor further noted that patients who have an NTRK mutation and meet all the indications in the US Food and Drug Administration-approved label for larotrectinib (Bayer’s Vitrakvi) can be considered to have advanced cancer. The patient can’t have been previously tested with Guardant360 for the same primary cancer, and the patient must have decided to seek further cancer treatment.

Source: https://www.genomeweb.com/reimbursement-news/moldx-finalizes-expanded-coverage-liquid-biopsies

Sign up for Billing Beat